The ARK™ Levetiracetam Assay is a homogeneous enzyme immunoassay intended for the quantitative determination of levetiracetam in human serum or plasma on automated clinical chemistry analyzers. The measurements obtained are used in the monitoring of levetiracetam levels to help ensure appropriate therapy.
- Excellent precision, even in trough concentrations
- Fast and efficient routine monitoring for levetiracetam
- Liquid, ready-to-use reagents, calibrators and controls
- Storage at 2-8°C
- On-board stability for at least 60 days
- Does not contain any harmful preservatives, only ≤ 0.09% sodium azide
Levetiracetam (KEPPRA®(S)-a-Ethyl-2-oxo-1-pyrrolidine acetamide) is an anti-convulsant drug approved for use as an adjunctive therapy in the treatment of epilepsy. It is also indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in adults and adolescents from 16 years of age with newly diagnosed epilepsy.
The reference ranges for seizure control have been proposed, which include concentrations from 6 to 46 μg/mL (35 to 270 μmol/L; trough samples). Circulating levels of levetiracetam (serum blood concentrations) may be affected by compliance, renal function, pregnancy, drug-drug interactions and timing of the sample draw. Furthermore, the clinical effect of these serum blood concentrations may be further altered by changes in progression in the severity of the disease and the addition or withdrawal of concomitant drugs which may interact pharmacodynamically with circulating levels of levetiracetam.